Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN LOCK FLUSH versus MIRADON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN LOCK FLUSH versus MIRADON.
HEPARIN LOCK FLUSH vs MIRADON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin potentiates the activity of antithrombin III, inactivating thrombin and activated factor X (FXa), thereby preventing fibrin formation and thrombus propagation.
MIRADON (anagrelide) inhibits cyclic nucleotide phosphodiesterase and the release of arachidonic acid from phospholipids, possibly by inhibiting phospholipase A2. It also suppresses megakaryocyte maturation and platelet production.
10-100 units/mL solution, 1-2 mL flush intravascularly after each catheter use or daily when catheter is not in use; typical adult dose: 10-100 units per flush.
2.5 mg orally twice daily (total daily dose 5 mg)
None Documented
None Documented
Terminal elimination half-life approximately 1-2 hours (mean 1.5 hours) at therapeutic doses; increases with dose; in renal failure, half-life prolonged up to 3-5 hours; clinical note: duration of effect short due to rapid clearance, requiring continuous infusion or frequent dosing.
Terminal elimination half-life is 8-12 hours in adults with normal renal function. In patients with creatinine clearance <30 mL/min, half-life may extend to 20-30 hours. The half-life supports twice-daily dosing in most patients.
Primarily renal via glomerular filtration and tubular secretion; about 50% excreted unchanged in urine; remainder metabolized in the liver and reticuloendothelial system (heparinase); fecal elimination negligible (<5%).
Renal excretion of unchanged drug accounts for 60-70% of the administered dose. Fecal/biliary excretion accounts for 20-25%, with the remainder as oxidative metabolites. Up to 10% is eliminated as glucuronide conjugates.
Category A/B
Category C
Anticoagulant
Anticoagulant